Nicholas Grund

2017

In 2017, Nicholas Grund earned a total compensation of $1.5M as Chief Commercial Officer at AMAG Pharmaceuticals, a 34% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$203,940
Option Awards$280,490
Salary$470,078
Stock Awards$536,200
Other$8,100
Total$1,498,808

Grund received $536.2K in stock awards, accounting for 36% of the total pay in 2017.

Grund also received $203.9K in non-equity incentive plan, $280.5K in option awards, $470.1K in salary and $8.1K in other compensation.

Rankings

In 2017, Nicholas Grund's compensation ranked 6,990th out of 14,666 executives tracked by ExecPay. In other words, Grund earned more than 52.3% of executives.

ClassificationRankingPercentile
All
6,990
out of 14,666
52nd
Division
Manufacturing
2,592
out of 5,770
55th
Major group
Chemicals And Allied Products
841
out of 2,074
60th
Industry group
Drugs
654
out of 1,730
62nd
Industry
Pharmaceutical Preparations
513
out of 1,329
61st
Source: SEC filing on April 25, 2018.

Grund's colleagues

We found four more compensation records of executives who worked with Nicholas Grund at AMAG Pharmaceuticals in 2017.

2017

William Heiden

AMAG Pharmaceuticals

Chief Executive Officer

2017

Edward Myles

AMAG Pharmaceuticals

Chief Financial Officer

2017

Julie Krop

AMAG Pharmaceuticals

Chief Medical Officer

2017

Joseph Vittiglio

AMAG Pharmaceuticals

General Counsel

News

You may also like